Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Market Vectors® Biotech ETF (BBH)

124.54
Delayed Data
As of Sep 04
 -0.46 / -0.37%
Today’s Change
95.00
Today|||52-Week Range
145.52
+7.94%
Year-to-Date

Investment Objective

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors  US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

No recent news for Market Vectors® Biotech ETF.

Performance

1 month-10.61% 3 years+35.04%
3 months-6.55% 5 years--
1 year+16.78% Since inception+40.85%
Data through 09/04/2015

Quote Details

Previous close$125.00
Open day’s range122.80 – 125.66
Net asset value (NAV)125.04 (09/03/2015)
Daily volume138,808
Average volume (3 months)157,551
Data as of 3:59pm ET, 09/04/2015

Peer Comparisonvs. Health ETFs

 BBHCategory
Performance 5-yr return--+26.72%
Expense Gross exp ratio0.41%0.46%
Risk 5 year sharpe ratio--1.60
Net assets$755.9M$1.9B
Average market cap$36.3B$38.7B
Average P/E24.226.0
Dividend / Share--0.21%

Competitors

XLV Health Care Select Sector SPDR® Fund
RYH Guggenheim S&P 500® Equal Weight Health...
VHT Vanguard Health Care Index Fund ETF Shar...

Holdings

Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
GILD Gilead Sciences14.71%
AMGN Amgen11.29%
CELG Celgene10.61%
BIIB Biogen6.03%
ALXN Alexion Pharmaceuticals Inc5.88%
REGN Regeneron Pharmaceuticals5.12%
INCY Incyte Corp5.06%
BMRN Biomarin Pharmaceutical Inc4.86%
VRTX Vertex Pharmaceuticals Inc4.68%
ILMN Illumina Inc4.22%

Partner Offers